Amit Sabnis
Assistant Professor
+1 415 502-4372

Education and Training

, 2019 Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 2014 Pediatric Hematology-Oncology, University of California, San Francisco
Residency, 2011 Pediatrics, University of California, San Francisco
M.D., 2008 School of Medicine, University of California, San Francisco
Cert, 2007 Medicine (Certificate in Biomedical Research), University of California, San Francisco

Publications

Ami Vijay Desai, Giles W. Robinson, Ellen M. Basu, Jennifer Foster, Karen Gauvain, Amit Sabnis, Suzanne Shusterman, Margaret E Macy, Luke Maese, Janet Yoon, Thomas Cash, Mohamed Abdelbaki, Kellie Nazemi, Brian D. Weiss, Saibah Chohan, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Amar J. Gajjar, Elizabeth Fox. Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):107-107.
Giles Robinson, Ami Desai, Karen Gauvain, Ellen Basu, Kathleen Dorris, Luke Maese, Amit Sabnis, Jennifer Foster, Suzanne Shusterman, Janet Yoon, Brian Weiss, Mohamed Abdelbaki, Mufiza Farid-Kapadia, Georgina Meneses-Lorente, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Amar Gajjar. PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi186-vi186.
Heunis JC, Cheah JW, Sabnis AJ, Wustrack RL. Use of three-dimensional printing and intraoperative navigation in the surgical resection of metastatic acetabular osteosarcoma. BMJ Case Rep. 2019 Sep 30; 12(9).
Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Rep. 2019 08 27; 28(9):2317-2330.e8.
Giles W. Robinson, Amar J. Gajjar, Karen Marie Gauvain, Ellen M. Basu, Margaret E Macy, Luke Devon Maese, Amit J. Sabnis, Jennifer Haunani Foster, Suzanne Shusterman, Janet Yoon, Brian D. Weiss, Mohamed Abdelbaki, Mufiza Farid-Kapadia, Georgina Meneses-Lorente, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Ami Vijay Desai. Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):10009-10009.
Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019 03; 25(3):185-197.
Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci. 2018 09 05; 131(17).
Ami Vijay Desai, Garrett M. Brodeur, Jennifer Foster, Stacey L. Berg, Ellen M. Basu, Suzanne Shusterman, Amit J. Sabnis, Margaret Macy, Janet Yoon, Karen Gauvain, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox. Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):10536-10536.
Cohen JN, Sabnis AJ, Krings G, Cho SJ, Horvai AE, Davis JL. EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature. Hum Pathol. 2018 11; 81:281-290.
Wattier RL, Levy ER, Sabnis AJ, Dvorak CC, Auerbach AD. Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services. Infect Control Hosp Epidemiol. 2017 09; 38(9):1039-1047.
Sabnis AJ, Bivona TG. HSP70 dependence in rhabdomyosarcoma: Seed or soil? Cell Cycle. 2017 01 17; 16(2):147-148.
Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016 08 09; 113(32):9015-20.
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47.
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
Amit Sabnis, Jonathan L. Finlay, Sabine Mueller. Neurologic Emergencies. Supportive Care in Pediatric Oncology. 2015 Jan 1; 71-96.
Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28.
Sabnis AJ, Bivona TG. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9.
Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell. 2009 Apr 07; 15(4):341-52.
Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59.
McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ, Zhang W, Fuchs H, de Angelis MH, Myers RM, Attardi LD, Barsh GS. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008 Aug; 40(8):963-70.
Amit J. Sabnis, Laurene S. Cheung, Kevin Shannon, Benjamin S. Braun. Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells. Blood. 2007 Nov 16; 110(11):778-778.
Margaret E.M. Van Meter, Ernesto Diaz-Flores, Joehleen A. Archard, Nikesh Kotecha, Amit J. Sabnis, Jonathan M. Irish, Garry P. Nolan, Kevin M. Shannon, Benjamin S. Braun. Multiparameter Flow Cytometric Analysis Reveals Aberrant Phosphorylation of a Network of Effector Molecules in Defined Populations of Kras Mutant Bone Marrow. Blood. 2005 Nov 16; 106(11):239-239.